TD Asset Management
CRVS icon

TD Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

TD Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
+123,738
New +$1.97M ﹤0.01% 988
2020
Q1 		– Sell
-13,583
Closed -$74K – 1383
2019
Q4 		$74K Sell
13,583
-29,995
-69% -$105K ﹤0.01% 1384
2019
Q3 		$131K Sell
43,578
-6,000
-12% -$25.2K ﹤0.01% 1318
2019
Q2 		$185K Buy
49,578
+2,200
+5% +$8.62K ﹤0.01% 1301
2019
Q1 		$190K Buy
47,378
+300
+0.6% +$1.27K ﹤0.01% 1311
2018
Q4 		$173K Buy
47,078
+600
+1% +$4.09K ﹤0.01% 1358
2018
Q3 		$399K Buy
46,478
+1,800
+4% +$18K ﹤0.01% 1336
2018
Q2 		$491K Buy
44,678
+400
+0.9% +$4.46K ﹤0.01% 1268
2018
Q1 		$511K Buy
+44,278
New +$419K ﹤0.01% 1195
2017
Q3 		– Sell
-10,744
Closed -$130K – 1306
2017
Q2 		$130K Sell
10,744
-13,305
-55% -$142K ﹤0.01% 1323
2017
Q1 		$499K Buy
24,049
+1,805
+8% +$28.3K ﹤0.01% 1215
2016
Q4 		$318K Sell
22,244
-1,300
-6% -$19.8K ﹤0.01% 1286
2016
Q3 		$387K Buy
+23,544
New +$339K ﹤0.01% 1247

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TD Asset Management's CRVS Position: Q1 2026 in Review

TD Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 123,738 shares worth $1.81M. The stake represents ﹤0.01% of the portfolio and ranks #988 among its holdings. This is a return to the name: TD Asset Management previously reported a position in CRVS as recently as Q4 2019.

TD Asset Management first reported a position in CRVS in Q3 2016 and has held it in 13 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • TD Asset Management held 123,738 shares of Corvus Pharmaceuticals worth $1.81M as of Q1 2026.
  • Corvus Pharmaceuticals was a new TD Asset Management position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #988 holding.
  • TD Asset Management first reported a position in Corvus Pharmaceuticals in Q3 2016 and has held it in 13 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.